Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM310 in adolescent atopic dermatitis
NCT06495229Phase 3Active, not recruiting
- Sponsor
- Keymed Biosciences
- Start
- Aug 2024
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of stapokibart in atopic dermatitis (AD), sponsored by Keymed Biosciences. Started Aug 2024; status: active, not recruiting.
02
Drugs
stapokibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06495229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06495229.